На этой странице перечислены больницы направления «Детская кардиология» (включая Atrial Septal Defect (ASD) Treatment) в Мумбаи, Индия, включая Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai и другие.
Спросите нас о «Atrial Septal Defect (ASD) Treatment» в Мумбаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 17 аккредитованных больниц (Детская кардиология) в Мумбаи, Индия
Рекомендуем🇮🇳 Nanavati Super Specialty Hospital
Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).
🇮🇳 Tata Memorial Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).
🇮🇳 Apollo Hospitals, Navi Mumbai
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 512 отзывов).
🇮🇳 Gleneagles Hospital, Mumbai
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 615 отзывов).
🇮🇳 Lilavati Hospital And Research Centre
Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 724 отзывов).
🇮🇳 Jaslok Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.6/5, 129 отзывов).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.6/5, 183 отзывов).
🇮🇳 Medicover Hospital, Navi Mumbai
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 143 отзывов).
🇮🇳 KIMS Hospitals, Thane
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 58 отзывов).
🇮🇳 Fortis Hospital, Mulund
Больница занимает 11-е место в этом списке по указанному рейтингу (4.5/5, 79 отзывов).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Больница занимает 12-е место в этом списке по указанному рейтингу (4.5/5, 83 отзывов).
🇮🇳 Wockhardt Hospital
Больница занимает 13-е место в этом списке по указанному рейтингу (4.4/5, 30 отзывов).
🇮🇳 Wockhardt Super Speciality Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.4/5, 48 отзывов).
🇮🇳 S. L. Raheja Hospital
Больница занимает 15-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Saifee Hospital
Больница занимает 16-е место в этом списке по указанному рейтингу (4.3/5, 97 отзывов).
🇮🇳 Dr. L H Hiranandani Hospital
Больница занимает 17-е место в этом списке по указанному рейтингу (4.3/5, 141 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Детская кардиология» указано среди её специализаций и она находится в Мумбаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «atrial septal defect (asd) treatment» в Мумбаи, Индия?
Выбор подходящей больницы для «atrial septal defect (asd) treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Детская кардиология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Atrial Septal Defect (ASD) Treatment»
Atrial Septal Defect (ASD) treatment encompasses a spectrum of interventions ranging from transcatheter device closure to open-heart surgical repair, offering closure rates exceeding 95% in experienced hands. International patients increasingly choose India and the UAE for ASD correction, drawn by world-class pediatric and adult congenital cardiology programs, significantly lower costs compared to Western countries, and seamless end-to-end coordination through GAF Healthcare. With GAF Healthcare, patients benefit from pre-screened JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, supported by dedicated case managers from the first inquiry through full recovery. Hospital Stay: 3–7 days (catheter-based closure: 2–3 days; open surgical repair: 5–7 days) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (transcatheter closure: approximately 2–3 weeks; open surgery: 4–6 weeks, subject to cardiologist clearance) • Success Rate: 95–98% (complete defect closure confirmed by post-procedural echocardiography)
Clinical Overview
An Atrial Septal Defect (ASD) is a congenital cardiac anomaly characterized by a persistent opening in the interatrial septum, permitting abnormal left-to-right shunting of oxygenated blood. The four principal morphological subtypes are secundum ASD (accounting for approximately 75% of cases and located in the region of the fossa ovalis), primum ASD (situated in the inferior septum and frequently associated with atrioventricular valve abnormalities), sinus venosus ASD (occurring near the superior or inferior vena cava orifices and commonly linked to partial anomalous pulmonary venous return), and the rare coronary sinus ASD. The hemodynamic consequence of sustained left-to-right shunting is volume overloading of the right heart, leading to progressive right ventricular dilation, pulmonary arterial hypertension, reduced exercise tolerance, and, in advanced cases, shunt reversal known as Eisenmenger syndrome. Uncorrected, significant ASDs — defined by a pulmonary-to-systemic flow ratio (Qp:Qs) greater than 1.5:1 or a defect diameter exceeding 10 mm — carry a lifetime risk of atrial arrhythmias (atrial fibrillation and flutter), paradoxical embolism, right heart failure, and substantially reduced life expectancy. The WHO functional classification and the Modified Bharat Ratna criteria (commonly employed in South Asian centers) are used alongside echocardiographic and hemodynamic data to stratify patients and guide intervention timing. Current guidelines from the American Heart Association (AHA/ACC 2018) and the European Society of Cardiology (ESC 2020) advocate for closure in symptomatic patients of any age and in asymptomatic patients with evidence of right ventricular volume overload, provided pulmonary vascular resistance remains below 5 Wood units. The contemporary standard of care prioritizes minimally invasive transcatheter device closure — predominantly using the Amplatzer Septal Occluder (ASO) or the Occlutech Figulla Flex II device — as the first-line approach for suitable secundum ASDs. Open surgical repair under cardiopulmonary bypass with patch or primary suture closure remains the gold standard for complex or large defects, primum and sinus venosus subtypes, and cases requiring concomitant anomalous pulmonary vein re-implantation. High-volume congenital heart programs in India and the UAE employ three-dimensional transesophageal echocardiography (3D-TEE), intracardiac echocardiography (ICE), and real-time fluoroscopic guidance to optimize procedural outcomes and minimize radiation exposure, particularly in pediatric patients.
Who is a Candidate?
• ELIGIBLE PATIENTS: • Children and adults with a confirmed secundum ASD with a stretched diameter of 5–38 mm, adequate septal rims (≥5 mm on most rims), and a Qp:Qs ratio >1.5:1 are ideal candidates for transcatheter Amplatzer or equivalent device closure. • Patients with primum ASD, sinus venosus ASD, or ASD associated with partial anomalous pulmonary venous return (PAPVR) who require surgical repair under cardiopulmonary bypass. • Symptomatic patients (dyspnea on exertion, fatigue, recurrent respiratory infections, failure to thrive in pediatric patients) regardless of defect size where hemodynamically significant shunting is confirmed. • Asymptomatic adults with echocardiographic evidence of right ventricular volume overload (RV end-diastolic dimension above the 95th percentile for age) per AHA/ACC Class I indications. • Patients with cryptogenic stroke or TIA attributed to paradoxical embolism through a confirmed significant ASD or PFO-ASD spectrum defect. • Adults with new-onset atrial fibrillation or flutter where ASD-related right atrial dilation is the identified substrate. • REQUIRED DIAGNOSTIC WORKUP: • Transthoracic Echocardiography (TTE): First-line imaging to identify defect location, size, direction and magnitude of shunt, and right ventricular function. • Transesophageal Echocardiography (TEE) or Intracardiac Echocardiography (ICE): Mandatory pre-procedural assessment for defect morphology, rim adequacy, and device sizing. • Three-Dimensional Echocardiography (3D-TEE): Increasingly used for precise en-face visualization and device sizing in complex defects. • Cardiac MRI (CMR): Definitive Qp:Qs quantification, volumetric assessment of biventricular function, and detection of anomalous pulmonary veins in sinus venosus ASD. • Right Heart Catheterization (RHC): Mandatory when pulmonary arterial hypertension is suspected; measures pulmonary vascular resistance (PVR) and response to vasodilators. • Chest X-Ray: Assessment of cardiomegaly, pulmonary plethora, and right atrial/ventricular prominence. • 12-Lead ECG: Detection of right bundle branch block (rSR' pattern in V1), right axis deviation, and arrhythmia burden. • Complete Blood Count, Coagulation Profile (PT/INR, aPTT), Renal and Liver Function Tests: Standard pre-procedural clearance. • CT Pulmonary Angiography (CTPA): Required for precise delineation of pulmonary venous anatomy in sinus venosus ASD planning. • CONTRAINDICATIONS: • Eisenmenger syndrome with irreversible pulmonary arterial hypertension (PVR >5 Wood units unresponsive to vasodilator testing) — closure is contraindicated as it may precipitate acute right heart failure. • Deficient or absent septal rim anatomy (particularly deficient aortic or posterior rims <5 mm on multiple aspects) making transcatheter closure technically non-feasible; surgical repair is the alternative. • Active systemic infection or sepsis prior to elective closure. • Uncorrected significant coagulopathy or thrombocytopenia (platelet count <50,000/µL) that cannot be optimized pre-procedurally. • Known allergy or hypersensitivity to nitinol (nickel-titanium alloy) — relevant to all nitinol-based occluder devices. • Anatomy unsuitable for femoral venous access (e.g., interrupted inferior vena cava without alternative access planning).
Treatment Options & Approaches
TRANSCATHETER DEVICE CLOSURE (First-Line for Eligible Secundum ASD) Transcatheter closure under TEE or ICE guidance via femoral venous access is the preferred approach for secundum ASDs with adequate rims and a stretched diameter up to approximately 38–40 mm. The Amplatzer Septal Occluder (ASO, Abbott) is the most extensively studied device, with over two decades of follow-up data demonstrating closure rates of 96–98% at one year. Alternative CE-marked and FDA-approved devices include the Occlutech Figulla Flex II, the Gore Cardioform Septal Occluder (preferred when aortic rim is deficient due to its pliable design), and the Lifetech CeraFlex in select centers. The procedure is performed under general anesthesia or conscious sedation, typically takes 45–90 minutes, and involves: femoral venous cannulation → transseptal sheath advancement → balloon sizing of the defect → device deployment under real-time imaging → confirmation of device position and residual shunt by color-flow Doppler TEE → sheath withdrawal. Patients receive aspirin (3–5 mg/kg/day, maximum 100 mg/day) for six months post-procedure and clopidogrel for three months in most institutional protocols. ICE-guided closure without general anesthesia is increasingly performed in adult patients at high-volume centers, reducing anesthetic risk and hospital stay to a single overnight observation. MINIMALLY INVASIVE SURGICAL REPAIR (Video-Assisted / Robotic-Assisted) For anatomically complex ASDs unsuitable for transcatheter closure — including primum, sinus venosus, and large secundum defects with deficient rims — minimally invasive surgical repair via right anterolateral mini-thoracotomy (3–4 cm incision) under cardiopulmonary bypass (CPB) has become the standard at high-volume centers. This approach avoids full sternotomy, reduces blood loss, shortens ICU stay to 24–48 hours, and results in superior cosmesis. Cardiopulmonary bypass is established via peripheral (femoral or direct aortic/caval) cannulation. Surgical techniques include: • Primary suture closure: Suitable for small to moderate secundum defects with adequate tissue margins. • Pericardial patch repair (autologous or bovine pericardium): Standard for large secundum, all primum (with concurrent mitral cleft repair if required), and sinus venosus ASDs. • Anomalous pulmonary vein re-implantation or Warden procedure: Applied in sinus venosus ASD with PAPVR to redirect pulmonary venous drainage to the left atrium. ROBOTIC-ASSISTED CARDIAC SURGERY (Da Vinci System) Select centers in India (Narayana Health, Apollo Hospitals, Fortis Malar) and the UAE (Cleveland Clinic Abu Dhabi) offer robotic-assisted ASD repair using the da Vinci Surgical System, enabling precise endoscopic repair through 8–12 mm port incisions with 3D magnified visualization. This approach is associated with zero sternotomy trauma, minimal blood transfusion requirements, and accelerated return to full activity (3–4 weeks versus 6–8 weeks for open sternotomy). Patient selection requires specific anatomical suitability and surgeon expertise. HYBRID PERVENTRICULAR CLOSURE For small infants and patients in whom standard transfemoral access is challenging due to vascular size constraints, some pediatric cardiac centers perform hybrid perventricular closure — a transesophageal-guided, off-bypass technique where the device is deployed directly through the right ventricular wall via a limited subxiphoid incision. This avoids femoral vessel injury and cardiopulmonary bypass in selected small patients. MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN BORDERLINE CASES In patients with borderline or moderate PAH (PVR 3–5 Wood units), a time-limited trial of targeted PAH pharmacotherapy — including phosphodiesterase-5 inhibitors (sildenafil, tadalafil) or endothelin receptor antagonists (bosentan) — may be prescribed for 3–6 months prior to reassessment for ASD closure eligibility. This 'treat-and-repair' strategy has demonstrated PVR reduction sufficient to enable safe closure in a subset of patients who would otherwise be deemed inoperable.
Восстановление
PHASE 1 — PRE-ARRIVAL & CONSULTATION (Weeks 1–3 before travel) • GAF Healthcare case manager reviews patient records, echocardiography reports, and prior investigations submitted via secure online portal. • Virtual consultation with a shortlisted congenital/adult congenital cardiologist at the chosen India or UAE center is arranged within 48–72 hours. • Cardiologist issues a formal opinion confirming candidacy for transcatheter or surgical closure and specifies which additional investigations (if any) are required on arrival. • GAF Healthcare assists with e-Medical visa application for India (typically approved within 24–72 hours) or UAE entry visa/visa-on-arrival processing, and arranges airport transfer, accommodation, and hospital appointment scheduling. PHASE 2 — ARRIVAL & PRE-PROCEDURAL WORKUP (Days 1–2 in-country) • Day 1: Airport pickup by GAF Healthcare representative; hotel or hospital guesthouse check-in; rest. • Day 2: Hospital admission or outpatient pre-assessment. Investigations completed on arrival typically include: TTE and/or TEE, 12-lead ECG, Chest X-Ray, complete blood count, coagulation profile, renal/liver function tests, blood typing and crossmatching, anesthesia fitness assessment, pediatric or adult cardiology consultation, and cardiac surgery consultation if open repair is planned. For sinus venosus ASD, CT pulmonary angiography or cardiac MRI is performed at this stage. • Anesthesiologist review and pre-operative counseling by the surgical/catheterization team. • Written informed consent obtained with multilingual support arranged by GAF Healthcare interpreter. PHASE 3 — THE PROCEDURE (Day 3) FOR TRANSCATHETER CLOSURE: • Patient is fasted from midnight. General anesthesia or conscious sedation is administered. • Femoral venous access is secured; right heart catheterization performed to confirm Qp:Qs and rule-out significant PAH. • Defect sizing by balloon occlusion or direct 3D-TEE measurement. • Appropriate device selected and deployed under continuous real-time TEE and fluoroscopic guidance. • Post-deployment assessment: device stability, disc position, residual shunting (none or trivial confirmed), AV valve and pulmonary vein flow unobstructed. • Procedure duration: 60–120 minutes. Recovery room observation: 2–4 hours. FOR OPEN / MINIMALLY INVASIVE SURGICAL REPAIR: • General anesthesia induction; arterial and central venous lines placed. • Surgical access: right anterolateral mini-thoracotomy or full median sternotomy depending on defect complexity. • Cardiopulmonary bypass established; heart arrested with cardioplegic solution (del Nido or St Thomas crystalloid cardioplegia). • Right atriotomy performed; defect repaired by primary suture or pericardial patch. • Associated lesions corrected concurrently (mitral cleft repair in primum ASD, Warden procedure for PAPVR). • CPB weaned; de-airing performed; right atrium closed; cardiac rhythm and hemodynamics confirmed. • Chest drain placed; incision closed in layers. • Procedure duration: 2–4 hours. Transfer to pediatric or adult cardiac ICU. PHASE 4 — IMMEDIATE POST-PROCEDURAL RECOVERY (Days 3–7) TRANSCATHETER: • Overnight in-hospital observation monitoring cardiac rhythm (telemetry), device position (chest X-ray), and vascular access site. • Discharge on Day 2 (post-procedure Day 1) with aspirin ± clopidogrel and activity restrictions. • Follow-up TTE before discharge to confirm device position and closure. SURGICAL: • ICU: 24–48 hours. Extubation typically within 4–8 hours post-operatively for uncomplicated cases. • Chest drains removed on post-operative Day 1–2. • Step-down cardiac ward Days 2–5; cardiac physiotherapy commenced (breathing exercises, supervised ambulation). • Hospital discharge on post-operative Day 5–7 following TTE confirmation of repair integrity. PHASE 5 — RECOVERY & FIT-TO-FLY PERIOD (Weeks 1–6 post-procedure) • TRANSCATHETER CLOSURE: Patients are advised to remain in-country for 2–3 weeks post-procedure. During this period, follow-up TTE at Day 7–10 and clinical cardiology review confirm device endothelialization is progressing and no device embolization or erosion has occurred. Light activity is resumed at Week 2; strenuous exertion avoided for 6 months. • SURGICAL REPAIR: Patients are advised to remain in-country for 4–6 weeks. Sternal/thoracotomy wound healing is assessed at Week 4; sutures or staples removed at Week 2. Physical milestones: independent ambulation by Day 5–7; climbing stairs by Week 2–3; return to light daily activities by Week 4; full unrestricted activity (for adults) by 8–12 weeks. • ANTICOAGULATION / ANTIPLATELET MONITORING: Post-device-closure patients are maintained on aspirin for 6 months with INR monitoring if anticoagulation is co-prescribed for concurrent atrial fibrillation. Surgical patients receive short-course prophylactic anticoagulation per institutional protocol. • ENDOCARDITIS PROPHYLAXIS: Recommended for 6 months following device closure (until complete endothelialization confirmed) and for all patients with residual defects or prior endocarditis history. • FINAL CLEARANCE: Formal fit-to-fly letter issued by treating cardiologist following final pre-departure echocardiogram and clinical review. Patients traveling long-haul are advised on in-flight hydration, compression stockings, and periodic ambulation to minimize thromboembolism risk.
Возможные риски
As with all cardiac interventions, ASD treatment carries procedural and post-procedural risks that vary by approach and patient-specific factors. For transcatheter device closure, recognized risks include device embolization or malposition (incidence <1% in experienced centers), air embolism during catheter manipulation, cardiac perforation or erosion — a rare but serious complication occurring in 0.1–0.3% of cases, most frequently when the aortic rim is deficient — cardiac tamponade requiring emergency pericardiocentesis or surgery, vascular access site hematoma or arteriovenous fistula, thrombus formation on the device surface during the endothelialization period (mitigated by antiplatelet therapy), and new-onset or worsening atrial arrhythmias. Nickel hypersensitivity reactions, while rare, can occur with nitinol-based devices and may require device explantation. For open surgical repair, risks include those common to cardiopulmonary bypass: systemic inflammatory response, coagulopathy, acute kidney injury (particularly in patients with pre-existing renal impairment), neurological events including stroke (risk estimated at 0.5–1.5% in adult congenital surgery), wound infection, pleural effusion, post-pericardiotomy syndrome (occurring in up to 20–30% of patients within weeks of pericardial opening, managed with NSAIDs or colchicine), and reoperation for residual shunt or bleeding. In patients with borderline or elevated pulmonary vascular resistance, closure may precipitate acute right heart failure; this risk is minimized by rigorous pre-procedural hemodynamic assessment. Long-term, a small percentage of patients develop new-onset atrial fibrillation following closure — particularly those who underwent repair in adulthood — due to pre-existing right atrial remodeling. Patients are counseled on all these risks during pre-procedural consent, and GAF Healthcare ensures that chosen centers have defined institutional protocols for managing each complication.
Почему GAF Healthcare
GAF HEALTHCARE END-TO-END COORDINATION FOR INTERNATIONAL PATIENTS MEDICAL VISA ASSISTANCE — INDIA: India offers a dedicated e-Medical Visa (e-MV) for international patients and up to two attendants (e-Medical Attendant Visa), processed entirely online through the Indian government portal with approvals typically issued within 24–72 business hours. GAF Healthcare's visa coordination team prepares and reviews all required documentation — including the official hospital invitation letter from the treating institution, passport-quality photographs, and supporting medical summaries — reducing rejection risk. The e-Medical Visa permits stays of up to 60 days and allows up to three entries within the visa validity period. VISA ASSISTANCE — UAE (DUBAI & ABU DHABI): Patients from over 50 nationalities (including GCC countries, the EU, the US, the UK, Canada, and Australia) receive visa-free entry or visa-on-arrival for up to 30–90 days in the UAE. For patients from other nationalities, GAF Healthcare coordinates with the hospital's international patient services department to facilitate a medical treatment visa application. The UAE's geographic position makes it highly accessible from South Asia, the Middle East, Africa, and Europe, with major hubs at Dubai International Airport (DXB) and Abu Dhabi International Airport (AUH) offering direct connections to over 250 cities. AIRPORT TRANSFERS: GAF Healthcare arranges private, air-conditioned vehicle transfers between the airport and the hospital or patient accommodation for patients and their attendants on arrival and departure. For pediatric patients or those arriving post-procedure in a weakened condition, medically equipped transfers with a trained escort can be arranged on request. DEDICATED PATIENT COORDINATORS & TRANSLATORS: Each patient is assigned a named GAF Healthcare case manager who remains the single point of contact from initial inquiry through post-discharge follow-up. Certified medical interpreters are available for Arabic, Russian, French, Swahili, Bangla, Urdu, Pashto, Amharic, and other languages to support informed consent, clinical communication, and discharge counseling. All interpretation is performed by individuals trained in medical terminology to ensure accuracy in consent and post-operative instruction. ACCOMMODATION FOR PATIENT & ATTENDANT: GAF Healthcare partners with hospitals offering on-campus guesthouses and with nearby hotels at negotiated rates for patient attendants. Options range from budget-friendly accommodation within walking distance of the hospital to premium serviced apartments. For pediatric ASD patients, child-friendly accommodation with kitchen facilities is prioritized to support dietary needs during recovery. For surgical patients requiring 4–6 weeks in-country, GAF Healthcare sources furnished monthly rental apartments at significantly lower rates than nightly hotel stays, reducing the overall cost of the medical trip. POST-DISCHARGE FOLLOW-UP COORDINATION: GAF Healthcare facilitates the transfer of detailed discharge summaries, echocardiography reports, procedural notes, and medication lists to the patient's home-country cardiologist or pediatrician within 48 hours of hospital discharge. Telemedicine follow-up appointments with the treating cardiologist are scheduled at 4 weeks and 12 weeks post-procedure for remote monitoring of recovery progress.
Частые вопросы о процедуре «Atrial Septal Defect (ASD) Treatment»
What is the cost of Atrial Septal Defect (ASD) treatment in India compared to the UAE?
How long do I need to stay in the country after ASD treatment before I am fit to fly home?
What is the success rate of ASD treatment, and what outcomes should I realistically expect?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «atrial septal defect (asd) treatment» в Мумбаи, Индия
Найдите лучшие больницы для «atrial septal defect (asd) treatment» в Мумбаи, Индия
На этой странице представлено 17 больниц в Мумбаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Atrial Septal Defect (ASD) Treatment» в Мумбаи, Индия
Сколько больниц направления «Детская кардиология» представлено в Мумбаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Мумбаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Atrial Septal Defect (ASD) Treatment» в Мумбаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.